Lorenzo Kiferle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8698209/publications.pdf

Version: 2024-02-01

26 papers

1,169 citations

687363 13 h-index 25 g-index

26 all docs

26 docs citations

26 times ranked

1870 citing authors

#	Article	IF	CITATIONS
1	Impulsivity traits and awareness of motor intention in Parkinson's disease: a proof-of-concept study. Neurological Sciences, 2022, 43, 335-340.	1.9	3
2	Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures. Epilepsia, 2022, 63, .	5.1	8
3	Brivaracetam as addâ€on treatment in focal epilepsy: A realâ€world timeâ€based analysis. Epilepsia, 2021, 62, e1-e6.	5.1	11
4	Intravenous brivaracetam in status epilepticus: A multicentric retrospective study in Italy. Seizure: the Journal of the British Epilepsy Association, 2021, 86, 70-76.	2.0	13
5	Epilepsy and brain channelopathies from infancy to adulthood. Neurological Sciences, 2020, 41, 749-761.	1.9	25
6	F5â€Social cognition in huntington's disease: evidence from a prospective study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A50.1-A50.	1.9	0
7	Spontaneous Dorsal Extramedullary Hematoma: A Rare Case Presenting as Isolated Thunderclap Headache. Headache, 2015, 55, 1263-1265.	3.9	1
8	Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology. Neurodegenerative Diseases, 2015, 15, 271-280.	1.4	3
9	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. Journal of Clinical Investigation, 2014, 124, 1340-1349.	8.2	202
10	Caudate dopaminergic denervation and visual hallucinations: Evidence from a 123I-FP-CIT SPECT study. Parkinsonism and Related Disorders, 2014, 20, 761-765.	2.2	30
11	Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain, 2013, 136, 400-411.	7.6	172
12	Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: A case report and an update on the state of art. Neuroscience Letters, 2013, 556, 1-4.	2.1	34
13	Nigral involvement and nigrostriatal dysfunction in Huntington's disease: Evidences from an MRI and SPECT study. Parkinsonism and Related Disorders, 2013, 19, 800-805.	2.2	13
14	Expanding the clinical phenotype of <i>DYT5</i> mutations: Is multiple system atrophy a possible one?. Neurology, 2013, 81, 301-302.	1.1	10
15	Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients. Parkinsonism and Related Disorders, 2012, 18, 59-62.	2.2	51
16	Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study. Human Brain Mapping, 2011, 32, 258-270.	3.6	181
17	Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. Neurobiology of Disease, 2010, 40, 216-221.	4.4	213
18	Nonmotor symptoms in Parkinson's disease: the dark side of the moon. Future Neurology, 2010, 5, 851-871.	0.5	10

#	Article	IF	CITATIONS
19	Unilateral periodic limb movements: Is this a pointer for atypical presentation of corticobasal degeneration syndrome?—A case report. Movement Disorders, 2009, 24, 2298-2299.	3.9	4
20	"Parkinson-dementia―diseases: A comparison by double tracer SPECT studies. Parkinsonism and Related Disorders, 2009, 15, 762-766.	2.2	25
21	Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S33-S37.	2.2	21
22	Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. Movement Disorders, 2008, 23, 2049-2054.	3.9	35
23	Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype. Neuroscience Letters, 2008, 444, 83-86.	2.1	11
24	The mtDNA A8344G "MERRF―mutation is not a common cause of sporadic Parkinson disease in Italian population. Parkinsonism and Related Disorders, 2008, 14, 381-382.	2.2	13
25	Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neuroscience Letters, 2007, 422, 228-231.	2.1	30
26	Cerebral Perfusional Effects of Cholinesterase Inhibitors in Alzheimer Disease. Clinical Neuropharmacology, 2004, 27, 166-170.	0.7	50